To evaluate the effectiveness of upadacitinib in reducing pain in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) compared to adalimumab and placebo.
Approach:
Key Findings:
In RA, upadacitinib showed greater pain reduction than adalimumab and placebo, especially in patients with inflammation.
In PsA, pain improvements with upadacitinib were similar to adalimumab in patients with inflammation attenuation.
Upadacitinib led to higher rates of inflammation attenuation compared to adalimumab and placebo.
Interpretation:
Pain reduction occurred with and without inflammation control, indicating that upadacitinib's direct effects on pain are significant, especially in RA.
Limitations:
Post hoc design of the study.
Different trial designs for RA and PsA.
Lack of early data in PsA.
Conclusion:
Upadacitinib is effective in reducing pain in RA and PsA, with notable direct effects independent of inflammation resolution.
